Changes in bone density and microarchitecture following treatment of Graves’ disease and the effects of vitamin D supplementation. A randomized clinical trial
Authors' conclusion
In newly diagnosed GD, 9 months of high dose vitamin D3 supplementation does not offer benefit by improving skeletal health. Treatment of thyrotoxicosis is associated with the recovery of BMD and microarchitecture.
Study context
- Population
- Newly diagnosed hyperthyroid patients with Graves' disease (GD); age 41 ± 14 years, 86% females
- Participants
- 86 participants
- Comparison
- Vitamin D3 70 µg/day vs placebo as add-on to antithyroid drugs (ATD)
- Primary endpoint
- BMD and bone microarchitecture (DXA and high resolution peripheral quantitative CT)
- Follow-up
- 9 months
Methodological detailsdouble-blinded, placebo-controlled
- Double-blinded
- Placebo-controlled
Primary result
As reported in the abstract
BMD and microarchitecture
- Compared to placebo, vitamin D3 did not improve bone mass density (BMD) or microarchitecture
Further findings
Response to ATD treatment (all patients): BMD and microarchitecture · 9 months
- Hip BMD increase
- 2% (95%CI: 1-4%)
- Cortical porosity change, tibia
- - 7% (95%CI: - 12 to - 2%)
- Cortical porosity change, radius
- - 14% (95%CI: - 24 to - 3%)
- Trabecular thickness increase, tibia
- 5% (95%CI: 2 - 9%)
- Trabecular thickness increase, radius
- 4% (95%CI: 1-7%)
Associations with BMD changes
- Changes in bone turnover markers (BTM), but not thyroid hormones, were associated with changes in BMD by DXA and with changes in the cortical compartment
Original publication
Changes in bone density and microarchitecture following treatment of Graves’ disease and the effects of vitamin D supplementation. A randomized clinical trial. Osteoporos Int. Published 12 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →